Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to one new employee.

GlobeNewsWire • Mar 6, 2026

Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that company management will present at the Leerink Partners Global Healthcare Conference in Miami, FL on Tuesday, March 10, 2025 at 1:00 p.m.

GlobeNewsWire • Mar 3, 2026

Fulcrum: Strong HbF Signal, Narrow TAM, Same 'Hold' Conclusion

Fulcrum Therapeutics (FULC) pivots to pociredir for severe sickle cell disease after discontinuing losmapimod. Pociredir's Phase 1 PIONEER data shows 7/12 patients hitting the ≥20% HbF threshold, but mean HbF just misses the mark. FULC's valuation is tied almost entirely to pociredir, with a risk-adjusted NPV of $136 million and $352.3 million in cash.

Seeking Alpha • Feb 26, 2026

Fulcrum Therapeutics, Inc. (FULC) Q4 2025 Earnings Call Transcript

Fulcrum Therapeutics, Inc. (FULC) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 24, 2026

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025

― Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ―

GlobeNewsWire • Feb 24, 2026

Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically relevant response, with progression toward pan-cellular HbF induction as F-cells increased from 31% to 63% ― ― 7 of 12 patients (58%) achieved absolute HbF levels ≥20%; all patients achieved at least a 6.5% absolute increase in HbF ― ― Improvements in markers of hemolysis, improved erythropoiesis, and a >1 g/dL increase in total hemoglobin ― ― 7 of 12 patients (58%) reported zero VOCs during the treatment period ― ― Pociredir was generally well-tolerated, with no treatment-related serious adverse events (SAEs) ― ― Fulcrum plans to initiate a potential registration-enabling trial in the second half of 2026 ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass.

GlobeNewsWire • Feb 24, 2026

Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, will host a conference call and webcast on Tuesday, February 24, 2026 beginning at 8:00 a.m.

GlobeNewsWire • Feb 17, 2026

Wall Street Analysts See a 75.71% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?

The consensus price target hints at a 75.7% upside potential for Fulcrum Therapeutics (FULC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Feb 12, 2026

Fulcrum Therapeutics, Inc. (FULC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Fulcrum Therapeutics, Inc. (FULC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 14, 2026

Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that company management will present at the 44th Annual J.P.

GlobeNewsWire • Jan 7, 2026